Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03308786 · ClinicalTrials.gov registry record · Phase 2
HIV Reservoir Reduction With Interleukin-2
A Phase 2 study, sponsored by Case Western Reserve University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03308786 is a Phase 2 study that was terminated before completion, run by Case Western Reserve University. The registered enrollment target is 9 participants.
The verdict
NCT03308786, a Phase 2 study, was terminated before completion, sponsored by Case Western Reserve University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV infection (viral load \<50 copies/mL).
Interventions
- DRUG Recombinant Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03308786
The ClinicalTrials.gov registry entry for NCT03308786 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Interleukin-2 is the first listed.
NCT03308786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03308786 about?
NCT03308786 is a clinical study titled "HIV Reservoir Reduction With Interleukin-2". The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV viral reservoir in up to 20 participants with chronically suppressed HIV in...
What is the current status of trial NCT03308786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2019-04-01. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT03308786?
The interventions under investigation include: Recombinant Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT03308786?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.